Abstract:The GABAA receptor mainly mediates inhibitory signal transmission in mammalian central nervous systems and is the key target of sedative-hypnotics. However, the long-term use of sedativehypnotics often leads to drug resistance, necessitating the development of novel sedative-hypnotics. This development can be achieved with novel scaffolds designed via the computer-aided drug design methods to obtain significant advantages. In this study, robust virtual screening models were established by identifying effective positive allosteric modulators of the GABAA receptor from ChEMBL and BindingDB databases. These compounds combined with randomly extracted negative compounds were firstly applied for a 10 fold cross validation and grid search to establish machine learning models which were subsequently evaluated in an independent test set. In this step, 4 machine learning methods and 6 fingerprints were used to establish 24 models. In the test set, the CDK_LR model performed the best (MCC = 0.751) and was used for subsequent virtual screening. Two effective molecular docking models were also established based on conformation 6D6T and 6D6U, wherein the root mean square deviation (RMSD) values of redocking experiments were 1.141 and 1.505 & ANGS; (1 & ANGS; = 0.1 nm), respectively. During the virtual screening, 41112 compounds from a commercial database were scanned by machine learning, molecular docking, and molecular mechanics-generalized Born surface area models. After the screening, 16 hits were obtained, 4 of which were structurally novel positive hits verified by whole-cell patch-clamp electrophysiology experiments. The compound GPR120 was verified experimentally at both the cell and animal levels. In cortical neurons recombinantly expressing & alpha;1 & beta;2 & gamma;2-type receptors, at 10 and 50 & mu;mol & BULL;L-1, GPR120 could potentiate GABA EC3-10 current by 71.5% and 163.8%, respectively. Total decomposition contribution analysis and point mutation experiment showed that the key binding site between GPR120 and the GABAA receptor is H102, similar to that of the positive drug Diazepam. To further verify GPR120 function at the animal level, locomotor activity and loss of righting reflex (LORR) tests were performed. GPR120 inhibited the locomotor activity of mice, which recovered after 6 h, indicating that GPR120 is a moderate sedative. In the pentobarbital sodium-induced righting reflex hour test, GPR120 (20 mg & BULL;kg-1) significantly shortened the time to start LORR and prolonged its duration compared with the saline control group. In summary, using integrated virtual screening methods, GPR120 was identified as a moderate sedative with a novel scaffold.

Curcumol allosterically modulates GABA(A) receptors in a manner distinct from benzodiazepines

Subunit-Specific Inhibition of Glycine Receptors by Curcumol

Curcumol from Rhizoma Curcumae Suppresses Epileptic Seizure by Facilitation of GABA(A) Receptors.

Safety Evaluation of Curcumol by a Repeated Dose 28-Day Oral Exposure Toxicity Study in Rats

Molecular mechanisms of GABA(B) receptor activation: new insights from the mechanism of action of CGP7930, a positive allosteric modulator

Design, Synthesis and Evaluation of Rivastigmine and Curcumin Hybrids As Site-Activated Multitarget-Directed Ligands for Alzheimer's Disease Therapy.

Natural Polyhydroxy Flavonoids, Curcuminoids, and Synthetic Curcumin Analogs as α7 nAChRs Positive Allosteric Modulators

Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1

2-Guanidine-4-methylquinazoline acts as a novel competitive antagonist of A type γ-aminobutyric acid receptors.

Curcumol effectively improves obesity through GDF15 induction via activation of endoplasmic reticulum stress response

Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface

Probes for the heterogeneity of muscimol binding sites in rat brain

Heteromeric GABAA receptor structures in positively-modulated active states

Heteromeric GABA<sub>A</sub>receptor structures in positively-modulated active states

Identification of Novel GABAA Receptor Positive Allosteric Modulators with Novel Scaffolds Via Multistep Virtual Screening

A-Type GABA Receptor as a Central Target of TRPM8 Agonist Menthol

Discovery of A Negative Allosteric Modulator of Gaba(B) Receptors

Electrophysiological Characterization of Methyleugenol: A Novel Agonist of Gaba(A) Receptors

Curcumol derivatives exhibit ameliorating effects on lipopolysaccharide-induced acute lung injury: Synthesis, biological evaluation, structure-activity relationship and action mechanism

GABA(B) receptor modulators potentiate baclofen-induced depression of dopamine neuron activity in the rat ventral tegmental area.

Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes